Labcorp has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its home collection kit that can detect Covid-19 and influenza A/B simultaneously. The kit can be used by individuals as young as two years of age. It is expected to help people determine whether they have Covid-19 from the safety of their home during flu season. The kit can be ordered online and the test results will be available in one or two days after Labcorp receives the completed collection kit.
Abu Dhabi is set to offer a wearable device to high-risk Covid-19 patient groups, according to The National News. The wrist-bourne device is reportedly capable of tracking oxygen saturation, temperature and heart rate. Healthcare staff monitor the data on a dashboard that charts the readings and will alert the patient if they spot any abnormalities. The move follows a successful pilot by the Abu Dhabi Health Services Company.
Adaptive Biotechnologies has presented new data regarding T-Detect Covid, a T-cell test, during IDWeek 2021. The new real-world data shows that T-Detect Covid can detect prior SARS-CoV-2 infection around 12 months after initial diagnosis in some patients. The test can be used to differentiate between natural SARS-CoV-2 infection and Covid-19 vaccine response. T-Detect is a specific test currently under development to detect multiple diseases, with T-Detect Covid being the first commercially available T-cell test to identify SARS-CoV-2 infection. The test has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).